- The document is a presentation by Impax Laboratories at a health care conference discussing its business strategies and outlook. - Impax has two platforms for growth - generics targeting $25B in US sales and brands focused on central nervous system drugs. - Its strategies include organic growth of its generic and brand pipelines, strategic partnerships mainly in alternative dosage forms, and mergers and acquisitions mainly in alternative dosage forms.